AlphAIAlphAI — Financial news for AI agents
marketscreener.comSEP 301 min read$IQV

UBS Adjusts IQVIA Price Target to $345 From $240, Maintains Buy Rating

UBS raised its price target for IQVIA from $240 to $345, maintaining a buy rating. The company's stock is currently trading at $270.77. RBC Capital Markets also noted a positive outlook for IQVIA due to accelerating drug approvals.

Original reporting
marketscreener.com
Published Sep 30, 2026, 1:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 30, 2026, 2:15 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$IQV
Bullish
high confidence
Mentioned
$IQV
Relevance
7/10
AlphAI data visualization · based on marketscreener.com
Decision brief

The 30-second read

$IQVBullishMed
01

Why it matters

The higher target may prompt short covering and new buying, modestly boosting the stock.

02

Market read

Analyst target changes are a common catalyst for short‑term price moves in the stock.

03

What to watch

Potential regulatory or payer reimbursement risks not reflected in the new target.

Relevance 7/10Novelty 6/10Timing: pre‑market today

Background

UBS analysts issued a new composite rating and increased the price target for IQVIA.

Company-level read

Ticker impact

$IQVBullishHigh confidence
Context

UBS raised IQVIA's price target to $345 from $240, indicating a bullish outlook.

Expected impact

likely upward pressure as investors price in the higher target

Evidence & confidence

Target raise reflects improved earnings expectations and may attract buying.

Market effects

Sector

May lift sentiment in the healthcare data and analytics sector.

Regional

US market focus; limited regional effect.

Global

Modest, confined to investors tracking US healthcare stocks.

Counterpoint

What could challenge this read

Target raise could be premature if upcoming earnings miss expectations.

Key entities

  • company
    IQVIA

    US‑listed healthcare data and analytics firm.

  • analyst
    UBS

    Investment bank providing the price‑target revision.

Read at source← All news

Related articles

SEP 19
$IQVHighAI 8/10

IQVIA Holdings (IQV) Prices $2b In Senior Notes, Is The Stock Still Undervalued?

IQVIA Holdings (IQV) priced a $2b senior notes offering due 2034. The company's share price has surged 58.8% in 90 days, with a 1-year return of 42.3%. Analysts estimate a fair value of $275.17, suggesting a modest undervaluation. However, risks include contract pricing pressure and higher leverage. The company's R&D solutions backlog and pipeline growth indicate sustained demand.

simplywall.st2 min
SEP 17
$IQVMed

Learn Why The Bull Case For IQVIA (IQV) Could Change Following AI Trial Platform Launch

IQVIA Holdings priced a $2.0b senior notes offering due 2034 to refinance debt and cover costs. The company launched IQVIA Predictive Clinical Development, an AI-driven platform aimed at accelerating clinical trials. Analysts project revenues of $20.4b and earnings of $2.0b by 2029, but debt remains a key risk. The AI platform could enhance growth and defend pricing power, though competition from in-house pharma tools is a concern.

simplywall.st3 min
SEP 9
$IQVHighAI 8/10

IQVIA stock rises amid $2 billion senior notes offering

IQVIA Holdings Inc. (IQV) shares rose 4.3% after announcing a $2 billion senior notes offering due 2034, with a 6.375% interest rate. Proceeds will redeem existing notes, repay debt, and cover offering fees. The offering is expected to close by September 23, 2026, and is targeted at institutional buyers and non-U.S. investors. IQVIA is a global provider of clinical research and healthcare intelligence services.

investing.com1 min